Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 9 Recurrence 5 Lymphoma, Non-Hodgkin 3 Lymphoma, T-Cell 1 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell 1 Leukemia, B-Cell 1 Leukemia 1 Hematologic Neoplasms 1 Graft vs Host Disease 1 Burkitt Lymphoma 1 Bronchiolitis Obliterans Syndrome 1

Interventions

Rituximab 43 Cyclophosphamide 26 fludarabine 15 ibrutinib 14 Vincristine 11 Prednisone 11 Doxorubicin 11 pirtobrutinib 10 Bendamustine Hydrochloride 10 obinutuzumab 9 polatuzumab vedotin 6 Inotuzumab Ozogamicin 6 tocilizumab 5 pembrolizumab 5 glofitamab 5 Gemcitabine 5 zanubrutinib 4 venetoclax 4 ublituximab 4 Lenalidomide 4 Brentuximab Vedotin 4 Antigens, CD19 4 tazemetostat 3 acalabrutinib 3 Everolimus 3 DTRMWXHS-12 3 veltuzumab 2 sepantronium 2 iberdomide 2 denileukin diftitox 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Lymphoma, B-Cell × Alemtuzumab × Clear all

NCT05607420 2025-08-24

NatHaLi-01

Cellectis S.A.

Phase 1/2 Recruiting

Recurrence, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡